HCWB HCW Biologics Inc.
Price Chart
Executive Summary
HCW Biologics announced preclinical data showing its fusion immunotherapeutic HCW11-040 prevented bronchopulmonary dysplasia (BPD) in an animal model, with IND-enabling studies expected to complete in H2 2027. The company plans to align with the reauthorized Rare Pediatric Disease PRV program, which could provide a priority review voucher upon approval. This is an early-stage discovery with no clinical data, no revenue, and a market cap of ~$2M, making the stock highly speculative.
Actionable Insight
This is a very early-stage preclinical discovery with no clinical data. The stock is highly speculative and may see a short-term pop on the news, but the catalyst is years away (IND filing in 2027+). Traders should watch for any partnership or licensing deals that could provide near-term capital. The $2M market cap suggests extreme volatility — position sizing is critical.
Key Facts
- HCW11-040 prevented BPD in a preclinical animal model during IND-enabling studies.
- IND-enabling studies expected to complete in H2 2027, with an IND filing planned immediately thereafter.
- BPD affects 10,000–15,000 U.S. cases annually with no known cure.
- Rare Pediatric Disease PRV program reauthorized through September 2029; company believes BPD indication aligns with the program.
- HCW11-040 is a second-generation pembrolizumab-based fusion immunotherapeutic designed to block checkpoint and engage costimulatory receptors.
- Company is clinical-stage with no approved products and a market cap of ~$2M.
Financial Impact
No financial data provided; company is pre-revenue with $2M market cap. Potential PRV value (historically ~$100M) is contingent on future approval.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- No revenue or approved products; company relies on dilutive financing.
- IND-enabling studies may be delayed or fail.
- RPD designation and PRV are not guaranteed.
- Extremely low market cap ($2M) creates high risk of delisting or reverse stock split.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294798 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
S-1
| $1.49 awaiting T+5 | awaiting T+5 | — | $1.28 (+13.80%) |
|
Jun 1, 2026
12d ago
|
8-K
| $2.07 $1.63 | ▲ +21.26% | ▲ +18.51% | $1.28 (+38.16%) |
|
May 27, 2026
16d ago
|
Insider Cluster
| $2.09 $1.68 | ▼ −19.62% | ▼ −19.57% | $1.28 (−38.76%) |
|
May 27, 2026
17d ago
|
8-K
| $1.94 $1.79 | ▼ −7.73% | ▼ −8.94% | $1.28 (−34.02%) |
|
May 21, 2026
22d ago
|
8-K
| $2.89 $2.07 | ▲ +28.37% | ▲ +30.05% | $1.28 (+55.71%) |
|
May 21, 2026
22d ago
|
Press Release
| $2.58 $2.09 | ▲ +18.99% | ▲ +20.59% | $1.28 (+50.39%) |
|
May 14, 2026
29d ago
|
8-K
| $1.22 $2.89 | ▼ −136.89% | ▼ −135.92% | $1.28 (−4.92%) |
|
May 14, 2026
29d ago
|
Press Release
| $1.22 $2.89 | ▼ −136.89% | ▼ −135.92% | $1.28 (−4.92%) |
|
May 14, 2026
4w ago
|
Press Release
| $0.3370 $2.58 | ▲ +665.58% | ▲ +666.30% | $1.28 (+279.82%) |
|
Apr 30, 2026
6w ago
|
8-K
| $0.4710 $0.3200 | ▼ −32.06% | ▼ −33.79% | $1.28 (+171.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access